Table 1.
Characteristics of studies included in meta-analysis of overall CAD
| Study author | Year | Country | Ethnicity | Study design | Type of CAD | Total cases/controls | Age Case / Control (Mean) |
Genotyping method | Quality score |
|---|---|---|---|---|---|---|---|---|---|
| MMP-9 (C1562T) | |||||||||
| Pollanen et al. | 2001 | Finland | European | Case-control | ACS | 109 / 167 | 33–69 / 33–69 | PCR-RFLP | 6 |
| Wang et al. | 2001 | Australia | Oceania | Case-control | Stable | 619 / 169 | 57.7 ± 0.5 / NR | PCR-RFLP | 7 |
| Cho et al. | 2002 | Korea | Asian | Case-control | Stable | 63 / 134 | NR / NR | PCR-RFLP | 5 |
| Kim et al. | 2002 | Korea | Asian | Case-control | Stable | 131 / 117 | 61.3 ± 7.9 / 59.3 ± 8.5 | PCR-RFLP | 6 |
| Jones et al. | 2002 | New Zealand | European | Case-control | Stable | 414 / 203 | 71.7 ± 7.6 / 70.8 ± 8.0 | PCR-RFLP | 8 |
| Tang et al. | 2005 | China | Asian | Case-control | ACS | 101 / 105 | NR / NR | PCR-RFLP | 5 |
| Chen et al. | 2005 | China | Asian | Case-control | ACS | 78 / 81 | NR / NR | PCR-RFLP | 5 |
| Meng et al. | 2006 | China | Asian | Case-control | Stable | 117 / 99 | NR / NR | PCR-RFLP | 5 |
| Nuzzo et al. | 2006 | Italy | European | Case-control | ACS | 49 / 123 | NR / NR | PCR-RFLP | 5 |
| Chen et al. | 2007 | China | Asian | Case-control | Stable | 150 / 70 | NR / NR | PCR-RFLP | 5 |
| Nanni et al. | 2007 | Italy | European | Case-control | ACS | 200 / 201 | 47.8 ± 6.2 / 47.0 ± 5.5 | PCR-RFLP | 7 |
| Wang et al. | 2007 | China | Asian | Case-control | ACS | 245 / 204 | NR / NR | PCR-RFLP | 8 |
| Zhang et al. | 2008 | China | Asian | Case-control | ACS | 92 / 95 | NR / NR | PCR-RFLP | 5 |
| Koh et al. | 2008 | Korea | Asian | Case-control | ACS | 206 / 173 | 61.1 ± 11.8 / 58.3 ± 11.8 | PCR-RFLP | 6 |
| Alp et al. | 2009 | Turkey | European | Case-control | Stable | 146 / 122 | 59.30 ± 9.1 / 57.30 ± 9.7 | PCR-RFLP | 6 |
| Wu et al. | 2009 | China | Asian | Case-control | ACS | 2517 / 689 | NR / 60.42 ± 9.07 | PCR-RFLP | 8 |
| Gao et al. | 2010 | China | Asian | Case-control | Stable | 96 / 78 | NR / NR | PCR-RFLP | 5 |
| Fallah et al. | 2010 | Iran | Asian | Case-control | Stable | 145 / 157 | 58.49 ± 9.12 / 55.35 ± 9.43 | PCR-RFLP | 6 |
| Yong et al. | 2010 | China | Asian | Case-control | ACS | 128 / 106 | NR / NR | PCR-RFLP | 5 |
| Ghaderian et al. | 2010 | Iran | Asian | Case-control | ACS | 400 / 200 | NR / 65.8 ± 5.9 | TaqMan | 8 |
| Zhi et al. | 2010 | China | Asian | Case-control | Stable | 762 / 555 | 67.46 ± 9.61 / 69.90 ± 11.48 | PCR-RFLP | 8 |
| Wang et al. | 2011 | China | Asian | Case-control | ACS | 384 / 451 | 55.6 ± 10.9 / 54.1 ± 10.3 | PCR-RFLP | 8 |
| Opstad et al. | 2012 | Norway | European | Case-control | Stable | 996 / 204 | 62 / NR | TaqMan | 8 |
| Han et al. | 2012 | China | Asian | Case-control | Stable | 91 / 101 | NR / NR | PCR-RFLP | 5 |
| Saracini et al. | 2012 | Italy | European | Case-control | Stable | 423 / 423 | 40–94 / 41–94 | Nano gene electronic microchip technology | 8 |
| Spurthi et al. | 2012 | India | Asian | Case-control | Stable | 100 / 100 | 56.73 ± 12.2 / 54.55 ± 14.38 | PCR-RFLP | 5 |
| Sewelam et al. | 2013 | Egypt | African | Case-control | ACS | 40 / 40 | NR / NR | PCR-RFLP | 5 |
| Wu et al. | 2013 | China | Asian | Case-control | ACS | 258 / 153 | 63.97 ± 12.32 / 63.61 ± 11.8 | PCR-RFLP | 7 |
| Xu et al. | 2013 | China | Asian | Case-control | Stable | 382 / 466 | 62 ± 12 / 62 ± 10 | PCR-RFLP | 8 |
| Rodriguez et al. | 2016 | Mexico | American | Case-control | ACS | 236 / 285 | 59 / 58 | PCR-RFLP | 8 |
| Yin et al. | 2016 | China | Asian | Case-control | Stable | 194 / 251 | 55.60 ± 10.42 / 56.21 ± 9.83 | PCR-RFLP | 7 |
| Beton et al. | 2016 | Turkey | European | Case-control | Stable | 200 / 200 | 60.2 ± 7.4 / 58.3 ± 7.7 | PCR-RFLP | 7 |
| Daraei et al. | 2016 | Iran | Asian | Case-control | ACS | 117 / 120 | 62.96 ± 12.80 / 52.55 ± 9.80 | PCR-RFLP | 6 |
| El-Aziz et al. | 2016 | Egypt | African | Case-control | ACS | 184 / 180 | 57.2 ± 10.9 / 58.8 ± 8.3 | PCR-RFLP | 7 |
| Qin et al. | 2016 | China | Asian | case-control | Stable | 261 / 261 | 58.75 ± 9.36 / 59.21 ± 10.10 | PCR-RFLP | 7 |
| Peksiene et al. | 2017 | Lithuania | European | Case-control | ACS | 518 / 645 | 61.9 ± 11.1 / 60.6 ± 11.9 | TaqMan | 8 |
| Mahmoodi et al. | 2017 | Iran | Asian | case–control | Stable | 100 / 100 | 59.4 ± 23.5 / 56.7 ± 29.5 | PCR-RFLP | 5 |
| Xu et al. | 2017 | China | Asian | Case-control | Stable | 264 / 186 | 59 ± 11.67 / 58 ± 10.72 | PCR-RFLP | 7 |
| Makrygiannis et al. | 2018 | Greece | European | Case-control | Stable | 175 / 166 | 72.7 ± 7.6 / 71.5 ± 7.1 | PCR-RFLP | 7 |
| Malkani et al. | 2019 | Iran | Asian | Case-control | Stable | 101 / 100 | 59.2 ± 10.2 / 47.3 ± 13.1 | PCR-RFLP | 5 |
| MMP-9 (R279Q) | |||||||||
| Nanni et al. | 2007 | Italy | European | Case-control | ACS | 200 / 201 | 47.8 ± 6.2 / 47.0 ± 5.5 | PCR-RFLP | 7 |
| Wu et al. | 2009 | China | Asian | Case-control | ACS | 2506 / 687 | NR / 60.42 ± 9.07 | PCR-RFLP | 8 |
| Zhi et al. | 2010 | China | Asian | Case-control | Stable | 762 / 555 | 67.46 ± 9.61 / 69.90 ± 11.48 | PCR-RFLP | 8 |
| Wang et al. | 2011 | China | Asian | Case-control | ASC | 384 / 451 | 55.6 ± 10.9 / 54.1 ± 10.3 | PCR-RFLP | 8 |
| Mishra et al. | 2012 | India | Asian | Cohort | Stable | 510 / 230 | NR/ 54.2 ± 8.5 | PCR-RFLP | 8 |
| Opstad et al. | 2012 | Norway | European | Case-control | Stable | 994 / 204 | 62 / NR | TaqMan | 8 |
| Fiotti et al. | 2017 | Italy | European | Case-control | Stable | 169 / 169 | 69–78 / 67–80 | Sequencing | 7 |
| MMP-9 (P574R) | |||||||||
| Zhi et al. | 2010 | China | Asian | Case-control | Stable | 762 / 555 | 67.46 ± 9.61 / 69.90 ± 11.48 | PCR-RFLP | 8 |
| Mishra et al. | 2012 | India | Asian | Cohort | Stable | 510 / 230 | NR / 54.2 ± 8.5 | PCR-RFLP | 8 |
| MMP-9 (R668Q) | |||||||||
| Zhi et al. | 2010 | China | Asian | Case-control | Stable | 762 / 555 | 67.46 ± 9.61 / 69.90 ± 11.48 | PCR–RFLP | 8 |
| Mishra et al. | 2012 | India | Asian | Cohort | Stable | 510 / 230 | NR / 54.2 ± 8.5 | PCR–RFLP | 8 |
NR, not reported; ACS, Acute coronary syndrome